Figure 4.
IDO1 deficiency suppressed seizures in a lithium-pilocarpine-induced epilepsy model. (A) Latency to status epilepticus (SE) onset after pilocarpine injection in the wild-type (WT) group and IDO−/− group. (B) Spontaneous recurrent seizures (SRS) frequency in the WT group and IDO−/− group. (C) SRS duration in the WT group and IDO−/− group. (D) SRS severity in the WT group and IDO−/− group. The data are presented as the mean ± SEM, n = 10–12 per group. *P < 0.05, ***P < 0.001 compared with the WT group.
